Any difference between the deceased patients and survivors were computed with 95% confidence interval. A P value of ≤0.05 was considered statistically significant. Results As described in the methodology, patients’ records for a 5-month period were analyzed. Between July and November 2004, there were 11944 patients Bortezomib admitted to the RLUH among which 11372 (95%) patients were discharged alive and 572
(5%) patients died during hospitalization. The number of male and female patients were 6078 (51 %) and 5866 (49%), respectively. The age (mean±SD) of survivors was Inhibitors,research,lifescience,medical 56.0±22.0 and that for the deceased patients was 78.0±13.0 years. Eighty four percent of the patients were admitted to the medical wards, 1% to the ICU, and the rest (15%) were admitted to the regardless surgical wards. Deceased patients were significantly older than survivors (P<0.0001) and needed a longer hospitalization Inhibitors,research,lifescience,medical (19±24 vs. 8±16 days, P<0.0001) (table 1). Table 1 The characteristics of patients who had laboratory tests done in the first 24 hours of admission and the
wards to which they were admitted in the Royal Liverpool University Hospital between Inhibitors,research,lifescience,medical Jul-Nov 2004 Of 1650 (550 deceased cases and 1100 survivor controls) selected patients, 876 (53%) were males, 774 (47%) females, 42 (3%) admitted to ICU, and 1426 (86%) to medical, and 182 (11%) to surgical wards. The distribution of percentages of patients admitted to different wards of the hospital is shown in figure 1. Figure 1 The distribution (in percentage) of all patients (deceased and matched controls, n=1650) who admitted to various wards of Royal Liverpool Inhibitors,research,lifescience,medical University Hospital between July to November 2004 and had laboratory test done in the first 24 hours of their admission. … The median WBC count for the deceased and surviving patients was 11.4×109/l and 9.4×10 9/l, respectively (table 1), and there was a significantly difference between these groups (P=0.03). The number of patients with a WBC count of >10×109/l were 804, which comprised of 335 (42%) deceased cases and 469 (62%)
matched controls Inhibitors,research,lifescience,medical (table 2). Table 2 The frequencies of strata of WBC counts and age (in years) of deceased patients (n=550) and matching survivors (n=1100) The mean±SD age of AV-951 all selected patients (cases and matched controls, n=1650) was 61.0±22.0 years. There was a significant (P<0.0001) difference between the age of deceased patients (78.0±13.0 years) and matched survivors (53.0±21.0 years). Deceased patients had a significantly (P<0.001) longer hospitalization than the survivors (9 vs. 2 days, (table 2). The number of cases with leukocytosis (WBC counts >10×109/l) were significantly (P=0.0001) more in deceased patients (335 out of 550) than that in surviving patients (469 out of 1100). Moreover, the number of cases with leuckopenia (WBC counts <4×109/l) were significantly (P=0.002) more in deceased patients (14 out of 550) than that in surviving patients (12 out of 1100) (table 2).